Orphan Drugs Market 2018; Booming CAGR of 11.6% | Worldwide Top 10 Key Merchant | Technological Innovations | Revenue and Forecasts - 2023
Market Research Future published a half – cooked research report on “Global Orphan drugs Market Research Report - Forecast to 2022”– Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2022.Global Orphan Drugs Market - Overview
The orphan drugs market is developing exponentially owing to the growing investment in research and development and unmet needs for rare diseases are the key factor driving the orphan drugs Market. The global market for orphan drugs is expected grow at a CAGR of 11.6% over the forecasted period.
Get Exclusive Sample Report @ https://www.marketresearchfuture.com/sample_request/2312
Currently, these orphan drugs are representing 35% of the total new drug approvals in the industry. The orphan drugs are disorders that affects a small percentage of the population. A pharmaceutical product aimed at rare diseases or disorders is known as an orphan drug. The major driving factor for the growth are extensive exclusivity, low marketing cost, legislative and tax benefits, government support leading to economic, and new technology development such as DNA recombinant, gene mapping, and hybridoma.
The limitation of distribution and commercialization channels are due to the differential availability of the product in the developed and developing countries due to social and economic factors.
Global Orphan Drugs Market - Key Players
Celgene Corporation (U.S.), F. Hoffmann- La Roche AG (Switerzland), Alexion Pharmaceuticals, Inc. (U.S.), Bayer AG (Germany), Takeda Pharmaceuticals Company Limited (Switerzland), Biogen Idec Limited (U.S.), Eli Lilly and Company (U.S.), Bristol-Myers Squibb Company (U.S.), Novartis AG (Switerzland), Vertex pharmaceuticals, Inc. (U.S.), Sanofi (France), Johnson & Johnson (U.S.), Aegerion Pharmaceuticals, Inc. (U.S.), Amgen Inc. (U.S.), GlaxoSmithKline plc (U.S.), Merck & Co., Inc. (U.S.), Boehringer Ingelheim GmbH (Germany), AstraZeneca plc (UK), and others are some of the prominent players at the forefront of competition in the global orphan drugs market and are profiled in MRFR Analysis.
Global Orphan Drugs Market - Industry Updates
Jan, 2017 Acucela Inc. received orphan drug FDA approval for emixustat for treatment of Stargardt disease. This approval is anticpated to be essential for the treatment of this genetic disease.
Nov, 2015 Ocata Therapeutics was acquired by Astellas Pharma to expand its product portfolio for treatment of retinal disorders such as age-related macular degeneration and Stargardt disease
June, 2015 Johns Hopkins University and Bayer Healthcare agreed to sign a five year collaboration agreement for developing treatment for diabetic macular edema, retinal vein occlusion, Stargardt's disease, geographic atrophy, and age-related macular degeneration
Get Your Customized Report @ https://www.marketresearchfuture.com/reports/orphan-drugs-market-2312
Global Orphan Drugs Market - Regional Analysis
The global orphan drugs market is segmented into four major regions including Americas, Europe, Asia Pacific, and Middle East and Africa region.
Globally, the Americas region is considered to be the largest market for orphan drugs. Factors such as the increasing government incentives, and high product demand are expected to promote market growth in the US region, which is reflected to be the highest revenue-generating region in the Americas.
The European regions is the second-largest market for Global orphan drugs. The upcoming market for orphan drugs is predicted to be subjugated by the developed regions with developing regions acting as a support pillar for its growth.
Asia Pacific will be the fastest growing regional market and is likely to be the key to the future. Middle East & Africa is expected to have limited but steady growth in the market.
Global Orphan Drugs Market - Company Analysis
This market is highly fragmented and is dominated by five major vendors including F. Hoffmann La Roche AG, Celgene Corporation, Bristol-Mayer Squibb Company, Novartis AG, and Pfizer Inc. as these are supposed to have extensive product portfolios. Factors such as the stringent rules and regulations, patent expiry of branded drugs, decreased R&D productivity, and high regulatory barriers are some significant challenges to the vendors during the forecast period.
Major Table of Content:
1 Introduction
1.1 Definition
1.2 Scope Of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.5 Market Structure
2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3 Market Dynamics
3.1 Drivers
3.2 Restraints
3.3 Opportunities
3.4 Challenges
3.5 Macroeconomic Indicators
4 Market Factor Analysis
4.1 Porter’s Five Forces Model
4.1.1 Bargaining Power Of Suppliers
4.1.2 Bargaining Power Of Customer
4.1.3 Intensity Of Competitor’s
4.1.4 Threat Of New Entrants
5 Global Orphan Drugs Market, By Application
5.1 Introduction
5.1.1 Blood-Related Disorders
5.1.2 Oncology
TOC Continued……
Get Prime Discount @ https://www.marketresearchfuture.com/check-discount/2312
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Contact Us:
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune - 411028
Maharashtra, India
Phone: +1 646 845 9312
Email: sales@marketresearchfuture.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Orphan Drugs Market 2018; Booming CAGR of 11.6% | Worldwide Top 10 Key Merchant | Technological Innovations | Revenue and Forecasts - 2023 here
News-ID: 1107029 • Views: …
More Releases from Market Research Future
Hydrofluoric Acid Market (CAGR) of 4%, Innovation Imperative Future Proofing You …
Hydrofluoric acid (HF) is a crucial chemical compound with a wide range of applications across various industries. Despite its hazardous nature, it plays an essential role in manufacturing processes, especially in the production of fluorine compounds. The global hydrofluoric acid market has been witnessing steady growth, driven by demand from end-user industries such as oil refining, pharmaceuticals, and electronics.
The Hydrodesulfurization Catalysts Market is projected to register a CAGR of over…
Palm Methyl Ester Derivative Market Size Projected to Grow at 5.92% CAGR, Reachi …
In recent years, the global market for palm methyl ester derivatives has witnessed significant growth, driven by various factors including environmental concerns, technological advancements, and the increasing demand for sustainable alternatives in various industries. Palm methyl ester derivatives, derived from palm oil, have emerged as versatile ingredients with applications spanning across sectors such as cosmetics, pharmaceuticals, lubricants, and more.
The Palm Methyl Ester Derivative Market Size was valued at USD 1.5…
Asia-Pacific Ceramic Tiles Market to Register Highest CAGR Growth of 7.50% by 20 …
The Asia-Pacific ceramic tiles market has been witnessing robust growth, driven by various factors such as increasing investments in residential and commercial construction, renovation activities, and the growing preference for aesthetically pleasing and durable flooring solutions. Countries like China, India, Japan, and South Korea have been leading the market growth, supported by strong manufacturing capabilities, technological advancements, and evolving consumer preferences.
Asia-Pacific Ceramic Tiles Market Size was valued at USD 141.2…
APAC Wallpaper Market to Register Highest CAGR Growth of 8% by 2032: Analysis by …
The APAC wallpaper market has witnessed significant growth in recent years, driven by factors such as rising disposable incomes, expanding construction activities, and growing awareness regarding interior decor. Countries like China, India, Japan, South Korea, and Australia have emerged as key contributors to the region's wallpaper market. Additionally, the increasing adoption of innovative wallpaper designs and patterns is fueling market growth further.
APAC Wallpaper Market Size was valued at USD 0.55…
More Releases for Orphan
Potential Opportunities of Orphan Drugs Market
As per Fortune Business Insights, the North America Orphan Drugs Market was worth US$ 67,136.0 Mn in 2017 and will continue to rise at a steady pace until 2025. This is mainly ascribable to the rising awareness among people regarding the use of novel drugs. In addition to this, North America is expected to offer attractive growth opportunities on the back of recent FDA approvals on the development of orphan…
Orphan Drug Pipeline & Regulatory Insight 2025
Orphan Drug Pipeline & Regulatory Insight 2025" Report Highlights:
Global Orphan Drug Market Overview: US$ 260 Billion Opportunity
Global Orphan Drug market by Segment
Regulatory Landscape: USA, Europe & Asia
Orphan Drug Designation & Reimbursement Policy: USA, Europe & Asia
Global Orphan Drug Clinical Pipeline Insight: 973 Drugs
Marketed Orphan Drug Clinical Insight: 366 Drugs
The global orphan drug market opportunity is expected to surpass US$ 260 Billion by 2025 as per…
Orphan Drugs for Cancer Pipeline Analysis
A huge market opportunity is offered by small patient population which suffers from rare or orphan diseases. Among the category of new orphan drugs, Oncology account for the largest disease group in recent years. It has been observed that majority of the orphan drugs in the clinical stages are for rare cancer disease drugs, and are in the late stages of the pipeline. Some of the drugs are being developed…
US Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the pharmaceuticals industry.…
Europe Orphan Drugs Pipeline Analysis
“Europe Orphan Drugs Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles under Orphan Drugs status in Europe. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. The information for particular drug…
Global Orphan Drug Pipeline Analysis
In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US & Europe, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the…